Program Description & Educational Objectives
In this activity, experts in the management of non-Hodgkin’s lymphoma (NHL) discuss the evolving treatment paradigm for follicular lymphoma (FL), with a focus on relapsed/refractory disease. Topics to be covered include the relationship between upfront treatment and subsequent management options, the nature of relapsed disease, advances in chemoimmunotherapy and transplant-based strategies, and the emerging generation of novel cytotoxics, targeted agents, antibodies, and other approaches in relapsed/refractory FL.
Upon completion of this activity, participants will be able to:
- Understand the use of established strategies for the management of patients with recurrent/refractory follicular lymphoma (FL), including cytotoxic agents, immunotherapy, and radioimmunotherapy, among others
- Analyze and interpret the most recent data pertaining to the efficacy and safety of emerging therapies for the treatment of relapsed/refractory indolent follicular lymphoma
Target Audience
This activity has been designed to meet the educational needs of hematologists, hematologists-oncologists, specialty nurses, and other clinicians involved in NHL.
Requirements for Successful Completion
In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME/CNE credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.
Media: Internet
Release and Expiration Dates: January 26, 2010 - January 25, 2011
Time to Complete: 30 minutes
Faculty & Disclosure
Course Director and Interviewee
Andre Goy, MD
Cancer Center Deputy Director
Head, Lymphoma Program
Director of the Tumor Bank
John Theurer Cancer Center at HUMC
Hackensack, New Jersey
Andre Goy, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Abbott Laboratories; Allos Therapeutics, Inc.; Biogen Idec Inc.; Genentech, Inc.; and Millennium: The Takeda Oncology Company.
Speakers Bureau participant with Abbott Laboratories; Allos Therapeutics, Inc.; Biogen Idec Inc.; Genentech, Inc.; and Millennium: The Takeda Oncology Company.
Interviewee
Steven H. Bernstein, MD
Co-Director of Lymphoma Biology Program
Professor of Medicine
University of Rochester
Rochester, New York
Steven H. Bernstein, MD,
has a financial interest/relationship or affiliation in the form of:
Consultant for Enzon Pharmaceuticals, Inc.; Genentech, Inc.; and Millennium: The Takeda Oncology Company.
CME Reviewer
Robert D. Marsh, MD
Professor and Program Director
Division of Hematology/Oncology
Department of Medicine
University of Florida
Gainesville, Florida
Robert D. Marsh, MD,
currently has no financial interests/relationships or affiliations in relation to this activity.
CNE Planner
Margaret Allee, RN, JD
Providence Health & Services
Portland, Oregon
Content Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education, Inc.
Carmine DeLuca
currently has no financial interests/relationships or affiliations in relation to this activity.
Sponsorship, Credit & Support
Physicians
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Florida College of Medicine and PVI, PeerView Institute for Medical Education. The University of Florida College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Florida College of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
Amedco is an approved provider of continuing nursing education by the Wisconsin Nurses Association Continuing Education Approval Program Committee, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.
The course is co-provided by Amedco and PVI, PeerView Institute for Medical Education. 0.5 contact hour(s).
Note: Not all state nursing boards will accept programs less than 1.0 hour in length for credit. Please click here to find out the status of your state.
This activity is supported by an educational grant from 
